LifeMD, Inc. (LFMD) Form 8-K — Nov 12, 2026
LifeMD closed a $12.5 million secured term loan on November 9, 2026 with Avenue Venture Opportunities Fund II and Avenue Growth Lending Fund III, secured by substantially all of the borrower subsidiaries' assets. The loan accrues interest at the greater of Prime + 4.50% or 11.50%, is interest-only for up to 24 months, and matures May 1, 2030. In connection with the financing, LifeMD issued lenders warrants for $625,000 of common stock at $2.32 per share (about 269,376 shares) and paid a $125,000 commitment fee. The closing required termination of the company's Citizens Bank credit facility, which had no amounts outstanding.
Key figures
- Debt Amount
- 12500000
- Interest Rate
- greater of Prime Rate + 4.50% or 11.50% per annum
- Maturity Date
- May 1, 2030
- Commitment fee
- 125000
- Prepayment penalty
- 1.00% to 3.00%
- Interest only period
- up to 24 months
- Revenue covenant ttm
- $150 million minimum trailing twelve-month net revenue beginning with fiscal quarter ending December 31, 2026
- Final payment percent
- 3.50% of original principal
- Commitment fee percent
- 1.00%
- Warrant underlying shares
- 269376
- Warrants purchased amount
- $625,000 in common stock
- Warrant stock purchase price
- $2.32 per share
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.